A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT)
Metrics: PDF 1700 views | HTML 2678 views | ?
Xiaobing Wang1,*, Xiuyi Zhi2,*, Zhaogang Yang3,*, Haimei Tian1, Yanfen Li1, Mo Li1, Wenya Zhao1, Chao Zhang1, Teng Wang1, Jing Liu1, Di Shen4, Cuining Zheng4, Dan Zhao5, Sheng Yang6, Jun Qi4, Hongwu Xin7,8, Alexander Stojadinovic9, Itzhak Avital10, L. James Lee3, Jianyu Rao1, Wei Zhang1
1Tumor Marker Research Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
2Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, PR China
3NSF Nanoscale Science and Engineering Center (NSEC), The Ohio State University, Columbus, OH, USA
4Laboratory of Clinical Biochemistry, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
5Department of Gynecological Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
6Department of Medicine, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
7The First Peoples’ Hospital of Jingzhou City, The First Hospital and Clinical Medical School of Yangtze University, Jingzhou, PR China
8Laboratory of Oncology, Center for Molecular Medicine, Medical School, Yangtze University, Huber, PR China
9Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
10P8-Medicine Ltd, Sussex, DE, USA
*These authors contributed equally to this work
Wei Zhang, email: [email protected]
Keywords: lung cancer, biomarker, early detection, MIC-1, screening
Received: February 03, 2017 Accepted: April 14, 2017 Published: April 27, 2017
Low Dosage Computerized Tomography (LDCT) has been shown to improve early detection of lung cancer and mortality rates in high-risk individuals, which was, however, limited by specifically coverage for heavy smokers and high rates of false positivity. Here, we aim to investigate a novel biomarker for early detection of lung cancer, and further extend to concentrate high-risk subjects for increasing specificity and coverage of LDCT. We performed retrospective blinded evaluation of lung cancer and healthy controls in training and validation cohorts. Macrophage inhibitory cytokine 1 (MIC-1) alone and panel were assessed. Our data showed the sensitivity of MIC-1 was 72.2% and 67.1% for lung cancer diagnosis and early diagnosis respectively, at 96.6% specificity, which were significantly higher than Cyfra21-1, NSE CA125, CEA and SCC. At 90% specificity, the panel of MIC-1, Cyfra21-1, CA125 and CEA provided 89.5% sensitivity for early diagnosis of lung cancer, which could be used to concentrate the high-risk subjects for further LDCT screening. We conclude that MIC-1 have great capacity in early lung cancer diagnosis. The algorithmic panel of MIC-1, Cyfra21-1, CA125 and CEA could be used to refine the preselection criteria of high-risk subjects, and thus might facilitate the widespread implementation of LDCT screening.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.